Logo

American Heart Association

  2
  0


Final ID: Mo3032

Cardiovascular Prognosis of Statin Users Developing Diabetes in Secondary Prevention: A Prospective Multicenter Study

Abstract Body (Do not enter title and authors here): Background
In primary prevention, statin use with new-onset diabetes mellitus (DM) was associated with increased atherosclerotic cardiovascular disease (ASCVD) risk. In high-risk and secondary prevention settings, the cardiovascular prognosis of statin users progressing to new-onset DM remains unclear.
Methods
We collected data from inpatients with or without baseline ASCVD from four medical centers affiliated to Qingdao University. Patients were categorized into 4 phenotypes: (1) statin non-users without diabetes; (2) statin users with incident diabetes; (3) statin users with pre-existing diabetes; and (4) statin users without diabetes. The primary outcome was ASCVD events. The stratified Cox proportional hazard model was used to investigate the association between the four distinct phenotypes and the risk of ASCVD.
Results
Among 12,800 high-risk patients, over a median follow-up of 118 days (interquartile range, 48-379 days), 1447 ASCVD events were documented. Compared with statin non-users without diabetes, statin users without diabetes (hazard ratio [95% confidence interval], 0.77 [0.65, 0.91], P=0.001) and statin users with pre-existing diabetes (0.80 [0.66, 0.99], P=0.035) were associated with lower risk of ASCVD, whereas statin users with new-onset diabetes were not (0.91 [0.70, 1.19], P=0.50), overall P for trend =0.013.(Figure 1) In patients with baseline ASCVD (i.e., secondary prevention settings), we observed similar findings (Figure 2)
Conclusions
In high-risk patients with pre-existing ASCVD, new-onset diabetes after statin use was likely associated with compromised cardiovascular benefits of statins.
  • Zhang, Yiwen  ( Qingdao University , Qingdao , China )
  • Li, Pengfei  ( Qingdao University , Qingdao , China )
  • Ji, Hongwei  ( Tsinghua University , Beijing , Beijing , China )
  • Author Disclosures:
    Yiwen Zhang: DO NOT have relevant financial relationships | Pengfei Li: No Answer | Hongwei Ji: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Medications in Motion: Innovating Pharmacotherapy for Enhanced Treatment Outcomes

Monday, 11/18/2024 , 01:30PM - 02:30PM

Abstract Poster Session

More abstracts on this topic:
More abstracts from these authors:
Race-Dependent Association of Inflammation and Cholesterol with Cardiovascular Mortality in US Population

Li Pengfei, Zhang Yiwen, Ji Hongwei

Thirty-Year Prevalence and Prognosis of the Cardiovascular-Kidney-Metabolic Syndrome in U.S. Females and Males

Ji Hongwei, Wong Tien, Sabanayagam Charumathi, Matsushita Kunihiro, Cheng Ching-yu, Rim Tyler Hyungtaek, Sheng Bin, Li Huating, Tham Yih Chung, Cheng Susan

You have to be authorized to contact abstract author. Please, Login
Not Available